Open Access Open Access  Restricted Access Subscription Access

Exploring Therapeutic Approaches: Drugs Targeting Lung Fibrosis

Muralinath E., Singh H. S., Vijay Digamber D, Shraddha D., Lalit Kumar S, Kalyan C., Archana Jain, Guruprasad M.

Abstract


Lung FIBROSIS. A condition  manifested by the progressive scarring of lung tissue and pses a significant health challenges worldwide. Pirfenidone is an anti-fibrotic drug and it is an FDA_ approved drug that performs by stopping the production of transforming growth factor_ beta (TGF_ beta ), a key player particularly in FIBROSIS. Another anti fibrotic drug such as nintedanonib targets multiple pathways participated in FIBROSIS, along with TGF_ beta pathway. Corticosteroids namely prednisone with an immune_ suppressing effect that can be used in decreasing inflammation linked to lung FIBROSIS. Mycophenolate mofetil is an immuno suppressive drug that has proved a very few benefits in certain cases of lung FIBROSIS. especially in connective tissue diseases. Mono clonal antibodies that are nintedanib plus sildenafil (a vasodilator ) are helpful in treating different aspects of FIBROSIS simultaneously. Connective tissue growth factor ( CTGF) is helpful in treating FIBROSIS. Stem cell therapy increases tissue repair and modulates the immune response particularly in lung FIBROSIS. Finally, it is concluded that the development of drugs targeting lung FIBROSIS indicates a critical area especially bin respiratory medicine.


Full Text:

PDF

References


Nakatsuka Y, Handa T, Kokosi M, Tanizawa K, Puglisi S, Jacob J, Sokai A, Ikezoe K, Kanatani KT, Kubo T, Tomioka H, Taguchi Y, Nagai S, Chin K, Mishima M, Wells AU, Hirai T. The Clinical Significance of Body Weight Loss in Idiopathic Pulmonary Fibrosis Patients. Respiration. 2018;96(4):338-347. [PubMed]

Walsh SLF. Imaging biomarkers and staging in IPF. Curr Opin Pulm Med. 2018 Sep;24(5):445-452. [PubMed]

Romagnoli M, Colby TV, Berthet JP, Gamez AS, Mallet JP, Serre I, Cancellieri A, Cavazza A, Solovei L, Dell'Amore A, Dolci G, Guerrieri A, Reynaud P, Bommart S, Zompatori M, Dalpiaz G, Nava S, Trisolini R, Suehs CM, Vachier I, Molinari N, Bourdin A. Poor Concordance between Sequential Transbronchial Lung Cryobiopsy and Surgical Lung Biopsy in the Diagnosis of Diffuse Interstitial Lung Diseases. Am J Respir Crit Care Med. 2019 May 15;199(10):1249-1256. [PubMed]

Homma S, Bando M, Azuma A, Sakamoto S, Sugino K, Ishii Y, Izumi S, Inase N, Inoue Y, Ebina M, Ogura T, Kishi K, Kishaba T, Kido T, Gemma A, Goto Y, Sasaki S, Johkoh T, Suda T, Takahashi K, Takahashi H, Taguchi Y, Date H, Taniguchi H, Nakayama T, Nishioka Y, Hasegawa Y, Hattori N, Fukuoka J, Miyamoto A, Mukae H, Yokoyama A, Yoshino I, Watanabe K., Ministry of Health, Labour and Welfare, the Study Group on Diffuse Pulmonary Disorders, Scientific Research/Research on Intractable Diseases, and Japanese Respiratory Society. Japanese guideline for the treatment of idiopathic pulmonary fibrosis. Respir Investig. 2018 Jul;56(4):268-291. [PubMed]

Cheng L, Tan B, Yin Y, Wang S, Jia L, Warner G, Jia G, Jiang W. Short- and long-term effects of pulmonary rehabilitation for idiopathic pulmonary fibrosis: a systematic review and meta-analysis. Clin Rehabil. 2018 Oct;32(10):1299-1307. [PubMed]

Tolle LB, Southern BD, Culver DA, Horowitz JC. Idiopathic pulmonary fibrosis: What primary care physicians need to know. Cleve Clin J Med. 2018 May;85(5):377-386. [PubMed]

Maher TM, Strek ME. Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. Respir Res. 2019 Sep 06;20(1):205. [PMC free article] [PubMed]

Idiopathic Pulmonary Fibrosis Clinical Research Network. Raghu G, Anstrom KJ, King TE, Lasky JA, Martinez FJ. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med. 2012 May 24;366(21):1968-77. [PMC free article] [PubMed]

Somogyi V, Chaudhuri N, Torrisi SE, Kahn N, Müller V, Kreuter M. The therapy of idiopathic pulmonary fibrosis: what is next? Eur Respir Rev. 2019 Sep 30;28(153) [PMC free article] [PubMed]

Chung JH, Oldham JM, Montner SM, Vij R, Adegunsoye A, Husain AN, Noth I, Lynch DA, Strek ME. CT-Pathologic Correlation of Major Types of Pulmonary Fibrosis: Insights for Revisions to Current Guidelines. AJR Am J Roentgenol. 2018 May;210(5):1034-1041. [PubMed]


Refbacks

  • There are currently no refbacks.